MacroGenics (MGNX) Competitors $1.55 -0.16 (-9.36%) As of 06/12/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MGNX vs. HUMA, KMDA, FULC, ITOS, RVNC, MBX, CKPT, RZLT, VIGL, and SLDBShould you be buying MacroGenics stock or one of its competitors? The main competitors of MacroGenics include Humacyte (HUMA), Kamada (KMDA), Fulcrum Therapeutics (FULC), iTeos Therapeutics (ITOS), Revance Therapeutics (RVNC), MBX Biosciences (MBX), Checkpoint Therapeutics (CKPT), Rezolute (RZLT), Vigil Neuroscience (VIGL), and Solid Biosciences (SLDB). These companies are all part of the "pharmaceutical products" industry. MacroGenics vs. Its Competitors Humacyte Kamada Fulcrum Therapeutics iTeos Therapeutics Revance Therapeutics MBX Biosciences Checkpoint Therapeutics Rezolute Vigil Neuroscience Solid Biosciences Humacyte (NASDAQ:HUMA) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, community ranking, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends. Do institutionals & insiders have more ownership in HUMA or MGNX? 44.7% of Humacyte shares are held by institutional investors. Comparatively, 96.9% of MacroGenics shares are held by institutional investors. 5.1% of Humacyte shares are held by insiders. Comparatively, 13.0% of MacroGenics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community believe in HUMA or MGNX? MacroGenics received 383 more outperform votes than Humacyte when rated by MarketBeat users. However, 70.97% of users gave Humacyte an outperform vote while only 61.71% of users gave MacroGenics an outperform vote. CompanyUnderperformOutperformHumacyteOutperform Votes4470.97% Underperform Votes1829.03% MacroGenicsOutperform Votes42761.71% Underperform Votes26538.29% Do analysts prefer HUMA or MGNX? Humacyte presently has a consensus price target of $11.71, indicating a potential upside of 386.07%. MacroGenics has a consensus price target of $5.71, indicating a potential upside of 268.66%. Given Humacyte's stronger consensus rating and higher probable upside, analysts plainly believe Humacyte is more favorable than MacroGenics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Humacyte 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00MacroGenics 0 Sell rating(s) 7 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.40 Which has better earnings and valuation, HUMA or MGNX? MacroGenics has higher revenue and earnings than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHumacyte$517K723.09-$110.78M-$0.69-3.49MacroGenics$152.43M0.64-$9.06M-$0.89-1.74 Does the media refer more to HUMA or MGNX? In the previous week, Humacyte had 6 more articles in the media than MacroGenics. MarketBeat recorded 14 mentions for Humacyte and 8 mentions for MacroGenics. Humacyte's average media sentiment score of 0.81 beat MacroGenics' score of 0.69 indicating that Humacyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Humacyte 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MacroGenics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is HUMA or MGNX more profitable? Humacyte has a net margin of 0.00% compared to MacroGenics' net margin of -69.07%. MacroGenics' return on equity of -89.42% beat Humacyte's return on equity.Company Net Margins Return on Equity Return on Assets HumacyteN/A -942.81% -93.82% MacroGenics -69.07%-89.42%-38.57% Which has more volatility & risk, HUMA or MGNX? Humacyte has a beta of 2, indicating that its share price is 100% more volatile than the S&P 500. Comparatively, MacroGenics has a beta of 1.66, indicating that its share price is 66% more volatile than the S&P 500. SummaryHumacyte beats MacroGenics on 10 of the 18 factors compared between the two stocks. Get MacroGenics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGNX vs. The Competition Export to ExcelMetricMacroGenicsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$97.79M$6.92B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.17%P/E Ratio-0.988.6727.2119.96Price / Sales0.64262.53408.49157.63Price / CashN/A65.8538.2534.64Price / Book0.636.597.074.69Net Income-$9.06M$143.75M$3.23B$248.14M7 Day Performance-12.92%0.68%0.68%0.91%1 Month Performance0.65%11.93%9.59%5.71%1 Year Performance-66.88%4.33%32.02%14.71% MacroGenics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGNXMacroGenics3.8338 of 5 stars$1.55-9.4%$5.71+268.7%-68.9%$97.79M$152.43M-0.98430Options VolumeGap DownHUMAHumacyte2.4109 of 5 stars$2.56-1.2%$11.71+357.6%-67.2%$401.76M$517K-1.91150Analyst RevisionKMDAKamada3.9377 of 5 stars$6.97+1.8%$14.67+110.4%+35.3%$400.64M$167.24M24.89360Positive NewsShort Interest ↑FULCFulcrum Therapeutics0.4333 of 5 stars$7.12-1.8%$6.29-11.7%-12.1%$384.33M$80M-22.97100Analyst RevisionITOSiTeos Therapeutics3.7588 of 5 stars$10.04-1.3%$15.86+57.9%-39.4%$384.27M$35M-3.1990Insider TradeRVNCRevance Therapeutics2.6109 of 5 stars$3.65flat$8.45+131.5%N/A$381.02M$234.04M-1.89500MBXMBX Biosciences2.0494 of 5 stars$11.36-0.1%$37.50+230.1%N/A$379.70MN/A0.0036Positive NewsCKPTCheckpoint Therapeutics2.5515 of 5 stars$4.26flat$4.33+1.7%N/A$370.71M$41K-2.3210RZLTRezolute2.7219 of 5 stars$4.31-2.7%$11.83+174.6%-19.7%$368.59MN/A-3.5340Positive NewsVIGLVigil Neuroscience4.0629 of 5 stars$7.88flat$10.80+37.1%+68.9%$367.78MN/A-3.8340Positive NewsHigh Trading VolumeSLDBSolid Biosciences3.9191 of 5 stars$4.62+1.8%$14.90+222.5%-42.2%$358.12M$8.09M-1.52100Positive NewsAnalyst Revision Related Companies and Tools Related Companies Humacyte Alternatives Kamada Alternatives Fulcrum Therapeutics Alternatives iTeos Therapeutics Alternatives Revance Therapeutics Alternatives MBX Biosciences Alternatives Checkpoint Therapeutics Alternatives Rezolute Alternatives Vigil Neuroscience Alternatives Solid Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGNX) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MacroGenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MacroGenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
